Clinical Neuropharmacology

0.9(top 50%)

impact factor

5.0K(top 5%)

papers

69.3K(top 5%)

citations

96(top 5%)

h-index

1.0(top 50%)

impact factor

5.3K

all documents

71.5K

doc citations

135(top 10%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis	Clinical Neuropharmacology	2010	650
2	Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms	Clinical Neuropharmacology	2001	613
3	Pharmacological Mechanisms of Opioid Analgesics	Clinical Neuropharmacology	1993	477
4	The Nighttime Problems of Parkinsonʼs Disease	Clinical Neuropharmacology	1988	382
5	Pharmacokinetics of Levodopa	Clinical Neuropharmacology	1984	295
6	Evaluation of the Abuse Liability of Modafinil and Other Drugs for Excessive Daytime Sleepiness Associated with Narcolepsy	Clinical Neuropharmacology	2000	283
7	Central Nervous System Side Effects Associated with Zolpidem Treatment	Clinical Neuropharmacology	2000	250
8	A “Glutamatergic Hypothesis” of Schizophrenia	Clinical Neuropharmacology	1989	239
9	A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia	Clinical Neuropharmacology	2000	237
10	Sleep Disruption in the Course of Chronic Levodopa Therapy	Clinical Neuropharmacology	1982	221
11	Falls and Parkinsonʼs Disease	Clinical Neuropharmacology	1989	215
12	Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia	Clinical Neuropharmacology	2010	211
13	Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets	Clinical Neuropharmacology	2003	206
14	Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers	Clinical Neuropharmacology	2005	203
15	MPTP	Clinical Neuropharmacology	1986	193
16	Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis	Clinical Neuropharmacology	2004	193
17	Hypersexuality with Antiparkinsonian Therapy	Clinical Neuropharmacology	1989	188
18	Anticonvulsant Drugs and Chronic Pain	Clinical Neuropharmacology	1984	178
19	Neurobiological Mechanisms Involved in Antidepressant Therapies	Clinical Neuropharmacology	1993	174
20	The Effects of Flumazenil in Neuropsychiatric Disorders	Clinical Neuropharmacology	1995	173
21	The Neurobiology of the Opsoclonus-Myoclonus Syndrome	Clinical Neuropharmacology	1992	172
22	Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease	Clinical Neuropharmacology	2010	172
23	The Pathophysiology of Serotonin Toxicity in Animals and Humans	Clinical Neuropharmacology	2005	169
24	Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated Monkeys	Clinical Neuropharmacology	1993	167
25	Buspirone in Levodopa-Induced Dyskinesias	Clinical Neuropharmacology	1994	167
26	N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases	Clinical Neuropharmacology	2013	165
27	Evaluation of the Hospital Anxiety and Depression Scale in Patients With Parkinson's Disease	Clinical Neuropharmacology	2002	164
28	Metronidazole-Induced Central Nervous System Toxicity	Clinical Neuropharmacology	2011	164
29	Tremors in Early Parkinsonʼs Disease	Clinical Neuropharmacology	1989	162
30	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)	Clinical Neuropharmacology	2004	161
31	Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial	Clinical Neuropharmacology	1998	157
32	A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease	Clinical Neuropharmacology	2008	154
33	Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa	Clinical Neuropharmacology	2000	153
34	Study of Circadian Melatonin Secretion Pattern at Different Stages of Parkinson's Disease	Clinical Neuropharmacology	2003	151
35	The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity	Clinical Neuropharmacology	2005	149
36	The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study	Clinical Neuropharmacology	2000	148
37	Intravenous Infusion of the NMDA Antagonist, Ketamine, in Chronic Posttraumatic Pain with Allodynia	Clinical Neuropharmacology	1995	147
38	Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase	Clinical Neuropharmacology	2007	145
39	Clinical Pharmacology and Mechanism of Action of Zonisamide	Clinical Neuropharmacology	2007	142
40	Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease	Clinical Neuropharmacology	2014	142
41	Rater-blinded, Prospective Comparison	Clinical Neuropharmacology	2006	140
42	Cladribine	Clinical Neuropharmacology	2011	140
43	Citalopram as Treatment of Depression in Patients With Epilepsy	Clinical Neuropharmacology	2004	138
44	Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease	Clinical Neuropharmacology	2002	137
45	Gender differences in Parkinson's disease	Clinical Neuropharmacology	1998	137
46	A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications	Clinical Neuropharmacology	2001	135
47	Minocycline as Adjunctive Therapy for Schizophrenia	Clinical Neuropharmacology	2008	133
48	Restless Legs Syndrome and Periodic Movements in Sleep	Clinical Neuropharmacology	1986	127
49	Thrombolytic Agents in the Treatment of Stroke	Clinical Neuropharmacology	1990	126
50	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil	Clinical Neuropharmacology	2002	122

Scientometrics

Overviews

Citing Bodies

Clinical Neuropharmacology

Top Articles